Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative...

Related Keywords

,Daniel Alkon ,Robert Weinstein ,Alan Tuchman ,Nemoursai Dupont ,Exchange Commission ,Drug Administration ,Nasdaq ,Synaptogenix Inc ,Cleveland Clinic ,Chief Scientific ,Orphan Drug Designation ,Private Securities Litigation Reform Act ,Autistic Spectrum Disorder Deficits ,Media Contacts ,Synaptogenix ,Nc ,